13.11
-1.19(-8.32%)
Currency In USD
Address
150 N. Radnor Chester Rd.
Radnor, PA 19087
United States of America
Phone
888-378-6240
Website
Sector
Healthcare
Industry
Biotechnology
Employees
51
First IPO Date
February 10, 2023
| Name | Title | Pay | Year Born |
| Mr. Jon Congleton | Chief Executive Officer & Director | 775,775 | 1963 |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder & Executive Director | 69,333 | 1977 |
| Mr. Adam Scott Levy | Chief Financial Officer & Secretary | 655,575 | 1978 |
| Dr. David M. Rodman M.D. | Chief Medical Officer | 726,950 | 1955 |
| Ms. Cindy Berejikian | Executive Vice President of Operations | 0 | N/A |
| Mr. Jeffrey N. Fellows | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Ms. Jessica Ibbitson | Senior Vice President of Clinical Operations | 0 | N/A |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC | 0 | N/A |
| Ms. Sarah Foster | Vice President of Human Resources | 0 | N/A |
| Ms. Danielle Bradbury | Senior Vice President of Quality Assurance | 0 | N/A |
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.